Lets head to where julie hyman has the latest. Julie fluctuating in a tight range. Maybe the tightest range of the year today. It will be interesting. So far, nothing unexpected has happened. We have seen gains and losses in the major averages as investors are weighing earnings and Economic Data this morning on inflation. Changinghat is really the macro narrative very much. First, i want to take a look at the s p over the course of the day and the narrow range. Happenedlike a lot has. A tight range as we bounced between gains and losses. Lets focus on individual movers we are watching where we are preliminary earnings that were below analyst estimates, saying it is seeing a weaker than estimated from china. Regulations out from the administration on offshore drilling are those shares are down seven sent. Mosaic is down as we got supply andsaying demand and the fertilizer and Agricultural Industries will remain there for the coming year h r block is declining after new proposal to have
Untouched by our counterterrorism effort. So in the future just recognize that in order to restore deterrence, were going to have to show capability, capacity, and resolve. Recognize this is an International Arms control agreement and not a very good one although there are some advantages, recognize the advantages as well. But its not a Friendship Treaty, and some people have tried to make it into a Friendship Treaty say its worthless. As a Friendship Treaty it would be worthless but its an arms control agreement that fell short of a lot of hopes but its not completely without some merit. We have allies out there. We have allies who want to rally to our side. I dont forget sitting with the king of jordan one day. We were working on his syrian refugee problem and i have seen refugees all around the world from the Southeast Asia to africa to the dalmatian coast. I have never seen i have been up in the refugee camps. I have never seen refugees as traumatized as those coming out of syria.
The day. The potential tieup is a complicated one, and it puts pfizer in a familiar position. Last year it unsuccessfully pursued astra zeneca, but as meg tirrell reports it now hopes for a different outcome. Reporter pfizer confirmed today its in friendly discussions about a potential combination with irish drug company allergan, the maker of botox. Analysts expect the deal value could total 150 billion. This comes a year and a half after pfizer abandoned its 120 billion bid for astrazeneca. After the british drugmaker resisted its advances in a nasty monthlong battle. Many think allergan will be more willing. The company is led by serial dealmaker brent saunders, who in just two years has amassed almost 150 billion in deal activity. He started at eye Company Bausch lomb where as ceo he sold the company to valeant for almost 9 billion in 2013. Less than a year later at the head of forest labs he engineered a 25 billion sale to activeus. After unexpectedly taking the ceo job there sand
The day. The potential tieup is a complicated one, and it puts pfizer in a familiar position. Last year it unsuccessfully pursued astra zeneca, but as meg tirrell reports it now hopes for a different outcome. Reporter pfizer confirmed today its in friendly discussions about a potential combination with irish drug company allergan, the maker of botox. Analysts expect the deal value could total 150 billion. This comes a year and a half after pfizer abandoned its 120 billion bid for astrazeneca. After the british drugmaker resisted its advances in a nasty monthlong battle. Many think allergan will be more willing. The company is led by serial dealmaker brent saunders, who in just two years has amassed almost 150 billion in deal activity. He started at eye Company Bausch lomb where as ceo he sold the company to valeant for almost 9 billion in 2013. Less than a year later at the head of forest labs he engineered a 25 billion sale to activeus. After unexpectedly taking the ceo job there sand
Pfizer did turn negative late in the day. The potential tieup is a complicated one, and it puts pfizer in a familiar position. Last year it unsuccessfully pursued astra zeneca, but as meg tirrell reports it now hopes for a different outcome. Reporter pfizer confirmed today its in friendly discussions about a potential combination with irish drug company allergan, the maker of botox. Analysts expect the deal value could total 150 billion. This comes a year and a half after pfizer abandoned its 120 billion bid for astrazeneca. After the british drugmaker resisted its advances in a nasty monthlong battle. Many think allergan will be more willing. The company is led by serial dealmaker brent saunders, who in just two years has amassed almost 150 billion in deal activity. He started at eye Company Bausch lomb where as ceo he sold the company to valeant for almost 9 billion in 2013. Less than a year later at the head of forest labs he engineered a 25 billion sale to activeus. After unexpecte